{
  "source": "PA-Notification-Skyclarys.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1412-3\nProgram Prior Authorization/Notification\nMedication Skyclarys® (omaveloxolone)\nP&T Approval Date 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nSkyclarys (omaveloxolone) is indicated for the treatment of Friedreich’s ataxia in adults and\nadolescents aged 16 years and older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Skyclarys will be approved based on the following criterion:\na. Diagnosis of Friedreich’s ataxia\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Skyclarys will be approved based on the following criterion:\na. Documentation of positive clinical response to Skyclarys therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or Medical Necessity may be in place.\n4. References:\n1. Skyclarys™ [package insert]. Plano, TX: Reata Pharmaceuticals, Inc.; December 2024.\n© 2025 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification - Skyclarys™ (omaveloxolone)\nChange Control\n5/2023 New program.\n5/2024 Annual review with no changes to coverage criteria. Updated\nreferences.\n5/2025 Annual review with no changes to coverage criteria. Updated\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}